Status:
UNKNOWN
Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Dutch Cancer Society
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Given the dismal prognosis of pancreatic cancer, detecting liver metastases early can avoid inappropriate therapy with the associated substantial risks, long-term hospital admissions and high costs, b...
Eligibility Criteria
Inclusion
- 18 years and older
- clinical suspicion of pancreatic cancer
- written (signed and dated) informed consent
Exclusion
- previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, ablation therapy)
- concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years
- contra-indications to undergo CT (due to e.g. extreme claustrophobia, untreatable contrast allergy, renal function impairment)
- contra-indications to undergo MRI (due to e.g. claustrophobia, untreatable contrast allergy, or not MRI compatible medical devices)
- insufficient command of the Dutch language to be able to understand the patient information or fill in the questionnaires
- pregnancy
Key Trial Info
Start Date :
December 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
465 Patients enrolled
Trial Details
Trial ID
NCT03469726
Start Date
December 22 2017
End Date
January 1 2023
Last Update
September 21 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Konstantopouleio general hospital
Athens, Greece
2
Radboudumc
Nijmegen, Gelderland, Netherlands, 6525GA
3
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands, 5223 GZ
4
Medisch Spectrum Twente
Enschede, Netherlands, 7512KZ